8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant To Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 7, 2009

PSYCHEMEDICS CORPORATION

(Exact Name of Registrant As Specified In Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

1-13738 (Commission File Number) 125 Nagog Park, Acton, Massachusetts 01720 (Address of Principal Executive Offices) (Zip Code)		58-1701987 (I.R.S. Employer Identification No.)
	(978) 206-8220 (Registrant’s Telephone Number, Including Area Code) N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions

(see General Instructions A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e-4(c))

.

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On May 7, 2009, Psychemedics Corporation issued a press release announcing preliminary results for the first quarter of 2009. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Limitation on Incorporation by Reference. The information in this Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

The following exhibits are filed herewith:

99.1 Press Release dated May 7, 2009.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto

duly authorized.

	PSYCHEMEDICS CORPORATION
Dated: May 7, 2009	By:	/s/ Raymond J. Ruddy
		Raymond J. Ruddy
		Vice President and Controller

EX-99.1

Psychemedics Corporation Announces First Quarter Results

Declares 51st Consecutive Quarterly Dividend

ACTON, Mass., May 7 /PRNewswire-FirstCall/ — Psychemedics Corporation (Nasdaq: PMD) today announced first quarter financial results for the period ended March 31, 2009.  The Company also announced a quarterly dividend of $0.17 per share payable to shareholders of record as of June 5, 2009 to be paid on June 19, 2009.  This will be the Company’s 51st consecutive quarterly dividend.

The Company’s revenue for the quarter ended March 31, 2009 was $4.1 million versus $5.7 million for the quarter ended March 31, 2008.  Net income for the quarter ended March 31, 2009 was $39 thousand or $0.01 per share, versus $890 thousand or $.17 per share for the comparable period last year.

Raymond C. Kubacki, Chairman and Chief Executive Officer, said, "There is no question that these are tough and challenging times.  However, we have been through tough and challenging times before.  While the current situation may be more severe, we, nonetheless, have learned to manage our business in difficult environments. Our focus is on maintaining our profitability and positioning our company for strong long term growth.”

Kubacki continued, “Our track record of profitability extends back through every year since 1993. Further, our strong balance sheet with $5.5 million in cash or cash equivalents and no long term debt provides us with not only a solid economic foundation to weather storms, but also a platform to take advantage of growth opportunities.”

Kubacki concluded, “Our directors share our confidence in the long-term future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we move forward.  Therefore, we are pleased to declare our 51st consecutive quarterly dividend."

Psychemedics is the world’s largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services.  Psychemedics’ clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.

The Psychemedics web site is www.drugtestwithhair.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995:  From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties.  In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements.  Actual results may differ from those stated in any forward-looking statements.  Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company’s filings with the Securities and Exchange Commission.

PSYCHEMEDICS CORPORATION

STATEMENTS OF INCOME

(UNAUDITED)

	Three Months Ended
	March 31,
	2009		2008
Revenue	$	4,078,837	$	5,708,863
Cost of Revenue		1,986,911		2,387,301
Gross Profit		2,091,926		3,321,562
Operating Expenses
General & Administrative		1,042,495		1,022,302
Marketing & Selling		871,464		798,645
Research & Development		125,046		117,780
Total Operating Expenses		2,039,005		1,938,727
Operating Income		52,921		1,382,835
Interest Income		15,507		111,771
Net Income Before Provision for Income Taxes		68,428		1,494,606
Provision for Income Taxes		29,903		605,000
Net Income	$	38,525	$	889,606
Basic net income per share	$	0.01	$	0.17
Diluted net income per share	$	0.01	$	0.17
Dividends declared per share	$	0.17	$	0.15
Weighted average common shares outstanding, basic		5,190,747		5,220,711
Weighted average common shares outstanding, diluted		5,204,876		5,308,962

PSYCHEMEDICS CORPORATION

BALANCE SHEETS

	March 31, 2009			December 31, 2008
	(UNAUDITED)
ASSETS
Current Assets:
Cash and cash equivalents	$	5,487,075		$	6,630,119
Accounts receivable, net of allowance of $246,478 in 2009 and $246,462 in  2008		2,741,716			3,398,455
Prepaid expenses		1,084,148			1,023,841
Other current assets		347,514			82,045
Deferred tax assets		490,762			449,398
Total current assets		10,151,215			11,583,858
Fixed Assets
Equipment & leasehold improvements		10,905,223			10,877,479
Less accumulated depreciation		(10,143,689	)		(10,047,755	)
Net Fixed Assets		761,534			829,724
Deferred tax asset		139,021			139,021
Other assets		74,716			75,183
Total Assets	$	11,126,486		$	12,627,786
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable	$	313,896		$	644,894
Accrued expenses		946,220			1,268,924
Deferred revenue		123,210			154,080
Total Current Liabilities		1,383,326			2,067,898
Shareholders' Equity
Preferred stock, $0.005 par value; 872,521 shares authorized, no shares issued or outstanding		-			-
Common stock, $0.005 par value; 50,000,000 shares authorized. 5,825,849 shares issued in 2009 and 5,815,000 shares issued in 2008		29,216			29,216
Paid-in capital		27,226,179			27,118,743
Accumulated deficit		(7,458,871	)		(6,614,114	)
Less - Treasury stock, at cost, 664,533 shares in 2009 and 606,797 shares in 2008.		(10,053,364	)		(9,973,957	)
Total Shareholders' Equity		9,743,160			10,559,888
Total Liabilities & Shareholders' Equity	$	11,126,486		$	12,627,786

Contact:	Raymond Ruddy
	Vice President and Controller
	(978) 206-8220
	raymondr@psychemedics.com

CONTACT: Raymond Ruddy, Vice President and Controller of Psychemedics Corporation, +1-978-206-8220, raymondr@psychemedics.com